Paulin Francisco, Doyle Tracy J, Fletcher Elaine A, Ascherman Dana P, Rosas Ivan O
Interstitial Lung Disease Clinic, Hospital María Ferrer, Buenos Aires, Argentina.
Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Rev Invest Clin. 2015 Sep-Oct;67(5):280-6.
The prevalence of clinically evident interstitial lung disease in patients with rheumatoid arthritis is approximately 10%. An additional 33% of undiagnosed patients have interstitial lung abnormalities that can be detected with high-resolution computed tomography. Rheumatoid arthritis-interstitial lung disease patients have three times the risk of death compared to those with rheumatoid arthritis occurring in the absence of interstitial lung disease, and the mortality related to interstitial lung disease is rising. Rheumatoid arthritis-interstitial lung disease is most commonly classified as the usual interstitial pneumonia pattern, overlapping mechanistically and phenotypically with idiopathic pulmonary fibrosis, but can occur in a non-usual interstitial pneumonia pattern, mainly nonspecific interstitial pneumonia. Based on this, we propose two possible pathways to explain the coexistence of rheumatoid arthritis and interstitial lung disease: (i) Rheumatoid arthritis-interstitial lung disease with a non-usual interstitial pneumonia pattern may come about when an immune response against citrullinated peptides taking place in another site (e.g. the joints) subsequently affects the lungs; (ii) Rheumatoid arthritis-interstitial lung disease with a usual interstitial pneumonia pattern may represent a disease process in which idiopathic pulmonary fibrosis-like pathology triggers an immune response against citrullinated proteins that promotes articular disease indicative of rheumatoid arthritis. More studies focused on elucidating the basic mechanisms leading to different sub-phenotypes of rheumatoid arthritis-interstitial lung disease and the overlap with idiopathic pulmonary fibrosis are necessary to improve our understanding of the disease process and to define new therapeutic targets.
类风湿关节炎患者中临床明显的间质性肺疾病患病率约为10%。另外33%未被诊断的患者存在可通过高分辨率计算机断层扫描检测到的间质性肺异常。与无间质性肺疾病的类风湿关节炎患者相比,类风湿关节炎-间质性肺疾病患者的死亡风险高出两倍,且与间质性肺疾病相关的死亡率正在上升。类风湿关节炎-间质性肺疾病最常被归类为普通型间质性肺炎模式,在机制和表型上与特发性肺纤维化重叠,但也可呈非普通型间质性肺炎模式,主要是非特异性间质性肺炎。基于此,我们提出两种可能的途径来解释类风湿关节炎和间质性肺疾病的共存:(i)当在另一个部位(如关节)发生的针对瓜氨酸化肽的免疫反应随后影响肺部时,可能会出现具有非普通型间质性肺炎模式的类风湿关节炎-间质性肺疾病;(ii)具有普通型间质性肺炎模式的类风湿关节炎-间质性肺疾病可能代表一种疾病过程,其中特发性肺纤维化样病理引发针对瓜氨酸化蛋白的免疫反应,从而促进类风湿关节炎的关节疾病表现。需要更多研究聚焦于阐明导致类风湿关节炎-间质性肺疾病不同亚表型及其与特发性肺纤维化重叠的基本机制,以增进我们对疾病过程的理解并确定新的治疗靶点。